Key Highlights

  • MasterCraft Boat Holdings (NASDAQ:MCFT) reported first-quarter transition period net sales of USD 154.1 million, up 123.4%, and raised guidance to USD 293 million to USD 297 million for the six-month period.
  • Passage Bio (NASDAQ:PASG) said pre-merger holders are expected to own about 6% of the combined company, with USD 20.2 million of cash and a going-concern warning.
  • NextCure (NASDAQ:NXTC) holds USD 8.7 million of cash, funding operations only into early 2027, ahead of a December 9, 2026 Merger vote.
  • Boundless Bio (NASDAQ:BOLD) expects to pay a special Cash Dividend of about USD 44 million to USD 48 million before its merger closes, while existing holders are expected to own about 3.8%.

MasterCraft Boat Holdings (NASDAQ:MCFT): A Completed Merger Doubles Net Sales

MasterCraft Boat Holdings (NASDAQ:MCFT) filed its Quarterly Report and held its call on November 10, 2026. The results cover the three months ended October 4, 2026, the first quarter of a six-month transition period created when the company moved to a December year-end after completing its Marine Products merger on May 15, 2026. Net sales of USD 154.1 million rose 123.4% from USD 69.0 million, including USD 59.3 million from the new Recreation and Sport Fishing segment, and legacy sales grew 37.4%. Consolidated gross Margin eased to 21.1% from 22.3% because the acquired brands carry lower margins. Income from continuing operations was USD 12.1 million, or USD 0.50 per diluted share (GAAP). Operating expenses rose to USD 20.5 million from USD 11.6 million, and adjusted EBITDA was USD 20.1 million. Management said it raised transition period guidance to adjusted Earnings of USD 0.75 to USD 0.80 a share, and the material gives no prior range. The company ended with USD 41.9 million of cash and no debt, and resumed Buybacks of about USD 4.8 million. The chief financial officer said some production moved from the second quarter into the first, so December shipments will likely dip.

Passage Bio (NASDAQ:PASG): A 6% Stake and a Going-Concern Warning

Passage Bio (NASDAQ:PASG) filed its quarterly report on November 10, 2026. Net loss narrowed to USD 4.7 million, or USD 1.47 per share, from USD 7.7 million, as research spending fell to USD 1.5 million from USD 4.3 million after a workforce cut of about 75% in April 2026. Cash was USD 20.2 million, and the filing says there is substantial doubt about continuing as a Going Concern within one year. The Remix Therapeutics merger split assumes about 65% for Remix holders, about 6% for Passage Bio holders and about 29% for financing investors, based on USD 100.0 million of concurrent financing and a USD 20.0 million valuation for the company. Management expects net cash of about USD 10.9 million at closing, so the ownership split can shift. Stockholders approved the merger, a reverse split and a name change on November 5, 2026, and closing is expected in the fourth quarter. It still depends on the financing and approval of a new listing application. Holders are also expected to receive contingent value rights tied to certain license payments.

NextCure (NASDAQ:NXTC): USD 8.7 Million of Cash Meets the Avere Vote

NextCure (NASDAQ:NXTC) filed its quarterly report on November 10, 2026. Net loss was USD 6.85 million against USD 8.62 million, and nine-month net loss fell to USD 31.53 million from USD 46.41 million. Research and Development expense dropped to USD 4.54 million, while general and administrative expense rose to USD 4.43 million, with USD 1.8 million of the increase tied to merger fees. Cash of USD 8.7 million funds operations only into early 2027, against an accumulated Deficit of USD 468 million, and the filing flags substantial doubt about continuing as a going concern. Stockholders vote on the Avere Therapeutics merger on December 9, 2026. Avere's private financing commitments total about USD 820.0 million, of which about USD 266.0 million comes from converting notes rather than new cash. Because new shares convert at a fixed exchange ratio, the added financing further reduces the share held by current holders, which the filing describes as substantial dilution. Current holders are expected to receive contingent value rights covering 90% of net proceeds from sales or licenses of legacy assets, with no assurance anything will be paid.

Boundless Bio (NASDAQ:BOLD): A Special Dividend Takes Shape Before the Serapha Merger

Boundless Bio (NASDAQ:BOLD) filed its quarterly report on November 10, 2026. The company agreed on June 22, 2026 to merge with Serapha Bio, a private gene editing company, and expects to declare a special cash dividend of about USD 44 million to USD 48 million before closing. That figure equals estimated net cash above zero and is subject to adjustment. Existing holders are expected to own about 3.8% of the combined company on a fully diluted basis. Third-quarter net loss was USD 5.4 million, or USD 0.23 per share, against USD 13.9 million, because research spending fell to USD 1.4 million from USD 10.7 million after trials were wound down. Cash and short-term investments were USD 62.9 million, with the dividend, merger costs, severance and wind-down expenses listed as the main uses, and the company paid USD 10.0 million to exit a San Diego lease. Closing needs approval from both sets of stockholders, continued listing and at least USD 200 million of gross financing raised by Serapha. A termination fee of USD 1.0 million may be payable, and if the merger fails the filing says substantial new funding would be needed.

Where Things Stand

Dilution is the common thread, and only one of the four is growing through its deal. MasterCraft Boat Holdings (NASDAQ:MCFT) more than doubled sales on a completed merger, though management flagged a lighter December quarter. Passage Bio (NASDAQ:PASG) offers holders about 6% of the combined company on the filing's assumptions. NextCure (NASDAQ:NXTC) faces a December 9, 2026 vote with USD 8.7 million of cash. Boundless Bio (NASDAQ:BOLD) plans a special dividend of about USD 44 million to USD 48 million, subject to adjustment. Next markers are the votes, the financings and closing conditions.